Alexander S Taylor1, Todd M Morgan2,3, David G Wallington4, Arul M Chinnaiyan1,2,3,5,6, Daniel E Spratt4,5, Rohit Mehra1,3,5. 1. Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan. 2. Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan. 3. Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, Michigan. 4. Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan. 5. Rogel Cancer Center, Michigan Medicine, Ann Arbor, Michigan. 6. Howard Hughes Medical Institute, Ann Arbor, Michigan.
Abstract
BACKGROUND: The Decipher test measures expression of 22 RNA biomarkers associated with aggressive prostate cancer used to improve risk stratification of patients to help guide management. To date, Decipher's genomic classification has not been extensively correlated with specific histologic growth patterns in prostatic adenocarcinoma. With a growing understanding of the clinical aggressiveness associated with cribriform growth pattern (CF), intraductal carcinoma (IDC), and percent Gleason pattern 4 (G4%), we sought to determine if their presence was associated with an increased genomic risk as measured by the Decipher assay. DESIGN: Clinical use of the Decipher assay was performed on the highest Gleason score (GS) tumor nodule of prostatectomy specimens from a prospective cohort of 48 patients, with GS varying from 7 through 9 to help guide clinical risk stratification. The tumors were reviewed for CF, IDC, and G4%, which were then compared to the Decipher score (0-1) and risk stratification (high vs not high). RESULTS: The presence of CF/IDC was significantly associated with Decipher risk score (P = .007), with a high-risk Decipher score in 22% vs 56% of patients without or with CF/IDC. On binary logistic regression analysis, G4% (odds ratio [OR] 1.04 per percent increase [95% confidence interval [CI], 1.02-1.06]; P = .0004) and CF predominant (OR, 9.60 [95%CI, 1.48-62.16]; P = .02) were significantly associated with a high-risk GC score. IDC did not reach significance (OR, 1.92 [95%CI, 0.65-5.67]; P = .24). CONCLUSIONS: Our findings add to an expanding knowledge base that supports G4% and CF/IDC as molecularly unique and clinically relevant features in prostatic adenocarcinoma. These histologic features should be standardly reported as they are associated with more aggressive prostate cancer. Future work should determine the independent information of these histologic findings that are relative to genomic assessment on long-term outcomes.
BACKGROUND: The Decipher test measures expression of 22 RNA biomarkers associated with aggressive prostate cancer used to improve risk stratification of patients to help guide management. To date, Decipher's genomic classification has not been extensively correlated with specific histologic growth patterns in prostatic adenocarcinoma. With a growing understanding of the clinical aggressiveness associated with cribriform growth pattern (CF), intraductal carcinoma (IDC), and percent Gleason pattern 4 (G4%), we sought to determine if their presence was associated with an increased genomic risk as measured by the Decipher assay. DESIGN: Clinical use of the Decipher assay was performed on the highest Gleason score (GS) tumor nodule of prostatectomy specimens from a prospective cohort of 48 patients, with GS varying from 7 through 9 to help guide clinical risk stratification. The tumors were reviewed for CF, IDC, and G4%, which were then compared to the Decipher score (0-1) and risk stratification (high vs not high). RESULTS: The presence of CF/IDC was significantly associated with Decipher risk score (P = .007), with a high-risk Decipher score in 22% vs 56% of patients without or with CF/IDC. On binary logistic regression analysis, G4% (odds ratio [OR] 1.04 per percent increase [95% confidence interval [CI], 1.02-1.06]; P = .0004) and CF predominant (OR, 9.60 [95%CI, 1.48-62.16]; P = .02) were significantly associated with a high-risk GC score. IDC did not reach significance (OR, 1.92 [95%CI, 0.65-5.67]; P = .24). CONCLUSIONS: Our findings add to an expanding knowledge base that supports G4% and CF/IDC as molecularly unique and clinically relevant features in prostatic adenocarcinoma. These histologic features should be standardly reported as they are associated with more aggressive prostate cancer. Future work should determine the independent information of these histologic findings that are relative to genomic assessment on long-term outcomes.
Authors: Daniel E Spratt; Jingbin Zhang; María Santiago-Jiménez; Robert T Dess; John W Davis; Robert B Den; Adam P Dicker; Christopher J Kane; Alan Pollack; Radka Stoyanova; Firas Abdollah; Ashley E Ross; Adam Cole; Edward Uchio; Josh M Randall; Hao Nguyen; Shuang G Zhao; Rohit Mehra; Andrew G Glass; Lucia L C Lam; Jijumon Chelliserry; Marguerite du Plessis; Voleak Choeurng; Maria Aranes; Tyler Kolisnik; Jennifer Margrave; Jason Alter; Jennifer Jordan; Christine Buerki; Kasra Yousefi; Zaid Haddad; Elai Davicioni; Edouard J Trabulsi; Stacy Loeb; Ashutosh Tewari; Peter R Carroll; Sheila Weinmann; Edward M Schaeffer; Eric A Klein; R Jeffrey Karnes; Felix Y Feng; Paul L Nguyen Journal: J Clin Oncol Date: 2017-11-29 Impact factor: 44.544
Authors: Adam I Cole; Todd M Morgan; Daniel E Spratt; Ganesh S Palapattu; Chang He; Scott A Tomlins; Alon Z Weizer; Felix Y Feng; Angela Wu; Javed Siddiqui; Arul M Chinnaiyan; Jeffrey S Montgomery; Lakshmi P Kunju; David C Miller; Brent K Hollenbeck; John T Wei; Rohit Mehra Journal: J Urol Date: 2016-02-23 Impact factor: 7.450
Authors: Charlotte F Kweldam; Intan P Kümmerlin; Daan Nieboer; Ewout W Steyerberg; Chris H Bangma; Luca Incrocci; Theodorus H van der Kwast; Monique J Roobol; Geert J van Leenders Journal: Mod Pathol Date: 2017-05-19 Impact factor: 7.842
Authors: Timothy C Brand; Nan Zhang; Michael R Crager; Tara Maddala; Anne Dee; Isabell A Sesterhenn; Jeffry P Simko; Matthew R Cooperberg; Shiv Srivastava; Inger L Rosner; June M Chan; Phillip G Febbo; Peter R Carroll; Jennifer Cullen; H Jeffrey Lawrence Journal: Urology Date: 2015-12-23 Impact factor: 2.649
Authors: Daniel E Spratt; Kasra Yousefi; Samineh Deheshi; Ashley E Ross; Robert B Den; Edward M Schaeffer; Bruce J Trock; Jingbin Zhang; Andrew G Glass; Adam P Dicker; Firas Abdollah; Shuang G Zhao; Lucia L C Lam; Marguerite du Plessis; Voleak Choeurng; Zaid Haddad; Christine Buerki; Elai Davicioni; Sheila Weinmann; Stephen J Freedland; Eric A Klein; R Jeffrey Karnes; Felix Y Feng Journal: J Clin Oncol Date: 2017-03-30 Impact factor: 44.544
Authors: R Jeffrey Karnes; Eric J Bergstralh; Elai Davicioni; Mercedeh Ghadessi; Christine Buerki; Anirban P Mitra; Anamaria Crisan; Nicholas Erho; Ismael A Vergara; Lucia L Lam; Rachel Carlson; Darby J S Thompson; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Timothy J Triche; Thomas Kollmeyer; Karla V Ballman; Peter C Black; George G Klee; Robert B Jenkins Journal: J Urol Date: 2013-06-11 Impact factor: 7.450
Authors: Matthew R Cooperberg; Jeffry P Simko; Janet E Cowan; Julia E Reid; Azita Djalilvand; Satish Bhatnagar; Alexander Gutin; Jerry S Lanchbury; Gregory P Swanson; Steven Stone; Peter R Carroll Journal: J Clin Oncol Date: 2013-03-04 Impact factor: 44.544
Authors: Bonnie Choy; Shane M Pearce; Blake B Anderson; Arieh L Shalhav; Gregory Zagaja; Scott E Eggener; Gladell P Paner Journal: Am J Surg Pathol Date: 2016-10 Impact factor: 6.394
Authors: R B Den; M Santiago-Jimenez; J Alter; M Schliekelman; J R Wagner; J F Renzulli Ii; D I Lee; C G Brito; K Monahan; B Gburek; N Kella; G Vallabhan; F Abdollah; E J Trabulsi; C D Lallas; L G Gomella; T L Woodlief; Z Haddad; L L C Lam; S Deheshi; Q Wang; V Choeurng; M du Plessis; J Jordan; B Parks; H Shin; C Buerki; K Yousefi; E Davicioni; V R Patel; N L Shah Journal: Prostate Cancer Prostatic Dis Date: 2016-08-30 Impact factor: 5.554
Authors: Giorgio Ivan Russo; Timo Soeterik; Ignacio Puche-Sanz; Giuseppe Broggi; Arturo Lo Giudice; Cosimo De Nunzio; Riccardo Lombardo; Giancarlo Marra; Giorgio Gandaglia Journal: Prostate Cancer Prostatic Dis Date: 2022-10-10 Impact factor: 5.455
Authors: Nancy Y Greenland; Matthew R Cooperberg; Anthony C Wong; Emily Chan; Peter R Carroll; Jeffry P Simko; Bradley A Stohr Journal: Investig Clin Urol Date: 2022-01
Authors: Amanda B Hesterberg; Brenda L Rios; Elysa M Wolf; Colby Tubbs; Hong Yuen Wong; Kerry R Schaffer; Tamara L Lotan; Giovanna A Giannico; Jennifer B Gordetsky; Paula J Hurley Journal: J Pathol Clin Res Date: 2021-02-18
Authors: Savannah R Duenweg; Xi Fang; Samuel A Bobholz; Allison K Lowman; Michael Brehler; Fitzgerald Kyereme; Kenneth A Iczkowski; Kenneth M Jacobsohn; Anjishnu Banerjee; Peter S LaViolette Journal: Tomography Date: 2022-03-02
Authors: L Lucia Rijstenberg; Tim Hansum; Charlotte F Kweldam; Intan P Kümmerlin; Sebastiaan Remmers; Monique J Roobol; Geert J L H van Leenders Journal: Histopathology Date: 2022-05-04 Impact factor: 7.778